New Trends And Future Developments Of Platinum Based Antitumor Drugs
951 Words Nov 28th, 2015 4 Pages
The purpose of this report is to go through the recent studies and scenarios to get an understanding of future developments of platinum-based antitumor drugs. Cisplatin was discovered in 1845 by an M Peyrone, which lead the molecule to be known as 'Peyrone 's salt '. However the authorization for cisplatin for the cures of ovarian and testicular cancer was given in 1978.
Currently in cancer treatments, Cisplatin is one of the three greatest consumed antitumor drugs in the world. However like any other drugs Cisplatin has its own advantage and disadvantages. One of the main disadvantages is sever toxicity such as neurotoxicity, ototoxicity and nephrotoxicity. Due to these side effects cisplatin can be used in a limited dosage for a period of time, therefore cisplatin have motivated the progress of platinum-based anticancer drugs.
From the time when cisplatin was introduced into the market, more than thousands of Pt complexes have been manufactured and assessed as possible antitumor agents. Then again Only Carboplatin received international approvals which then lead to routine clinical use. The main advantage of carboplatin was lower toxicity comparing to cisplatin therefore it can be used in higher dosage.
Unluckily carboplatin is still distributed intravenously and it’s only effective on similar range of tumors as cisplatin. After few years two other Pt…